ReviewFrontiers in medicine2016
Emerging Threats in Antifungal-Resistant Fungal Pathogens.
Review in Frontiers in medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
171 citing papers in PubMed.
- Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study.Indian journal of pharmacologyTrial
- Designing a chimeric multi-epitope vaccine against Candida auris using reverse vaccinology approach targeting the agglutinin-like protein N-terminal domain.Scientific reports · 2026Article
- CYP51C Y319H and H349R substitutions cannot confer azole resistance inMicrobiology spectrum · 2026Article
- Voriconazole Activity AgainstMolecules (Basel, Switzerland) · 2026Article
- An indole dimer antifungal metabolite from a rice seed endophyte inhibits ergosterol biosynthesis in fungal pathogens.Applied and environmental microbiology · 2026Article
- Synthesis of some novel coumarin-based heterocycles, elucidation of their antifungal behavior, molecular docking and computational studies.Scientific reports · 2026Article
- Antimicrobial, anticancer activities and molecular docking of eco-friendly chitosan nanocapsule loaded with biosynthesized titanium nanoparticles byFrontiers in microbiology · 2026Article
- Interconnected worlds: a comprehensive review of fungal defenses, antimicrobial resistance, and their evolutionary dynamics.IMA fungus · 2026Review
- Calcium transport systems as virulence determinants: Mechanistic insights into fungal pathogenicity and antifungal resistance.Virulence · 2025Review
- Repositioning Antimicrobial Peptides Against WHO-Priority Fungi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Article
- Pathogen Enzyme-Mediated Alkoxyamine Homolysis as a Killing Mechanism ofJournal of fungi (Basel, Switzerland) · 2025Article
- Synthetic Human Lactoferrin Peptide hLF(1-11) Shows Antifungal Activity and Synergism with Fluconazole and Anidulafungin TowardsAntibiotics (Basel, Switzerland) · 2025Article
- Discovery of Novel Inhibitors ofMolecules (Basel, Switzerland) · 2025Article
- Antifungal activity of guanidine compounds.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Development of a tri-species wound model for studying fungal-bacterial interactions and antimicrobial therapies.Biofilm · 2025Article
- Antifungal activity of polyphenolic compounds against fluconazole-susceptible and -resistantIranian journal of microbiology · 2025Article
- Culture-Dependent and -Independent Wastewater Surveillance for Multiple Pathogenic Yeasts.Journal of fungi (Basel, Switzerland) · 2025Article
- Article
- PHGDH/SYK: a hub integrating anti-fungal immunity and serine metabolism.Cell death and differentiation · 2024Article
111 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of antifungal drugs in the therapy of fungal diseases can lead to the development of antifungal resistance. Resistance has been described for virtually all antifungal agents in diverse pathogens, including Candida and Aspergillus species. The majority of resistance mechanisms have also been elucidated at the molecular level in these pathogens. Drug resistance genes and genome mutations have been identified. Therapeutic choices are limited for the control of fungal diseases, and it is tempting to combine several drugs to achieve better therapeutic efficacy. In the recent years, several novel resistance patterns have been observed, including antifungal resistance originating from environmental sources in Aspergillus fumigatus and the emergence of simultaneous resistance to different antifungal classes (multidrug resistance) in different Candida species. This review will summarize these current trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.